Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25
Shots:
- Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg- day 1-21- qd) + acalabrutinib (100mg- day 1-28- bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
- In the 13 patients who underwent disease assessment following the R2A regimen- ORR (69%) and CR (31%)- @6-mos. PFS (83%) and only one patient experienced disease progression after the initial objective response
- Throughout the study- out of 22 patients- dose reduction was performed in 3 and 1 patients for lenalidomide and acalabrutinib respectively due to hematologic toxicities. The data indicate that the R2A regimen was well tolerated in Korean r/r BCL patients- with initial analysis in non-GCB DLBCL patients showing a promising response
Click here to read full press release/ article
Ref: Celltrion | Image: Celltrion
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com